Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Presented in this paper is the data from clinical laboratory examination of 50 Korean atomic-bomb survivors (Hiroshima and Nagasaki, Japan, 1945). Of them, 15 survivors were karyotyped from their lymphocyte culture for both “stable” and “unstable” types of chromosomal aberrations. Eight of their offspring were also tested for the chromosomal changes and SCE as well. The results are as follows: 1. All survivors were found to have suffered from various diseases, particularly from respiratory diseases. Two had malignancies, viz., one case having squamous cell carcinoma of uterine cervix and another, adenocarcinoma of stomach. 2. Serum total protein and serum albumin levels were found to have decreased in 18% and 27% of the survivors, respectively. Alkaline phosphatase, SGOT, IgG and IgM increased in 22%, 6.3%, 36.7% and 13.6% of the survivors, respectively. IgA was within normal limit in all cases. 3. Stable type of chromosomal aberrations was discovered in none of the survivors and the offspring examined. However, approximtely 50% of the survivors showed a significantly higher incidence of chromatid breakage than normal controls. 4. None of the offspring showed the chromatid breakage, but 75% of them showed significantly higher rate of SCE when compared to controls.
Pubmed ID: 3154835
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Clinical trial under the Urinary Incontinence Treatment Network to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s) after surgery. Follow-up will be a minimum of two years and up to four years.
View all literature mentions